Tau pathology (neurofibrillary tangles and dystrophic neurites) is a key hallmark of Alzheimer’s disease (AD) and has become an important focus in research, clinical trials, and clinical practice, partly due to improvements in methods to detect tau pathology in vivo through positron emission tomography (PET)1,2. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.